SIMPONI ARIA® (golimumab) DOSING FOR ADULT PATIENTS1

AN EFFICIENT*

30

MINUTE INFUSION

GIVEN ONCE EVERY 8 WEEKS

AFTER STARTER DOSES1,2

As Few As

6

Times a Year

AFTER STARTER DOSES1

  • *“Efficient” is defined as the total amount of time required to administer SIMPONI ARIA®
  • For adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS), 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 8 weeks, after starter doses at Weeks 0 and 41
  • For adult patients with moderately to severely active RA, SIMPONI ARIA® is given in combination with methotrexate (MTX)1
  • Liquid solution in a single-use vial with no reconstitution required1
  • Short infusion time1 allows for flexible scheduling
  • Weight-based dosing for adult patients1
administered

For adult patients with RA, PsA, or AS, 2 mg/kg is administered once every 8 weeks after starter doses at Weeks 0 and 4.

combination

For adult patients with RA, SIMPONI ARIA® should be given in combination with methotrexate.

arrows

The efficacy and safety of switching between intravenous and subcutaneous formulations and routes of administration have not been established.

clipboard

Prior to initiating SIMPONI ARIA® and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection. Prior to initiating SIMPONI ARIA®, test patients for hepatitis B viral infection.

magnifying

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with SIMPONI ARIA®. Discontinue SIMPONI ARIA® if a patient develops a serious infection, an opportunistic infection, or sepsis.

diagnostic

For patients who develop a new infection during treatment with SIMPONI ARIA®, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient and initiate appropriate antimicrobial therapy and closely monitor them.

tested

All patients should be tested for hepatitis B virus (HBV) infection before initiating TNF-blocker therapy. For patients who test positive for hepatitis B surface antigen, consultation with a physician with expertise in the treatment of hepatitis B is recommended before initiating TNF-blocker therapy.

warning

The risks and benefits of SIMPONI ARIA® should be considered prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing a TNF-blocker in patients who develop a malignancy.

solution

SIMPONI ARIA® Injection is a colorless to light yellow solution available in packs of 1 vial. Each single-dose vial contains 50 mg of SIMPONI ARIA® per 4 mL of solution.

refrigerated

SIMPONI ARIA® should be refrigerated at 36°F to 46°F (2°C to 8°C) and protected from light. Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake.

temp

If needed, SIMPONI ARIA® may be stored at room temperature up to 77°F (25°C) for a maximum single period of 30 days in the original carton to protect from light. Once SIMPONI ARIA® has been stored at room temperature, do not return the product to the refrigerator. If not used within 30 days at room temperature, discard SIMPONI ARIA®.

Infusion Experience

Interactive Infusion Administration Video for SIMPONI ARIA®

GO TO VIDEO

Please see the full Prescribing Information for SIMPONI ARIA® for dosing and administration instructions.

References: 1. SIMPONI ARIA® [Prescribing Information]. Horsham, PA: Johnson & Johnson. 2. Data on file. Johnson & Johnson.